Literature DB >> 11730333

Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore.

L C Santora1, Z Kaymakcalan, P Sakorafas, I S Krull, K Grant.   

Abstract

The binding of fully human monoclonal antibodies (MAbs) D2E7 and 2SD4 to their antigen, human tumor necrosis factor-alpha (TNFalpha), was investigated by BIAcore, cation exchange (CIEX), and size exclusion liquid chromatography (SEC) using ultraviolet and laser light scattering detectors. D2E7 has a higher affinity for TNFalpha than 2SD4 and the two antibodies (Abs) differ by 12 amino acids in the antigen (Ag) binding regions. A BIAcore biosensor instrument was used to determine the association, k(on) and dissociation, k(off), rate constants for the binding of TNFalpha to D2E7 and 2SD4. The HPLC methods were used to resolve and to study D2E7, 2SD4, and TNFalpha molecules and the noncovalent complexes of D2E7 and 2SD4 with TNFalpha. The CIEX method demonstrated that all D2E7 charged-variants bound TNFalpha equally well. There was no preferential binding for any one of D2E7 charged-variants to TNFalpha. D2E7 and 2SD4 Abs were resolved by the CIEX method. When a mixture of D2E7 and 2SD4 was mixed with excess TNFalpha, D2E7. TNFalpha complexes were formed before any 2SD4. TNFalpha complexes. Thus, the CIEX method was able to rank the affinities of the MAbs. D2E7 and TNFalpha formed complexes of 600-5000 kDa. The molecular weights of various D2E7. TNFalpha complexes were determined by a SEC method with light scattering (LS) and refractive index (RI) detectors. Upon overnight incubation, a 598-kDa complex emerged as the most stable and the only D2E7. TNFalpha complex. The molar ratio of D2E7 to TNFalpha in this complex was approximately 1:1. Based on molecular weights and the molar ratio, an immune complex, consisting of alternating three D2E7 and three TNFalpha molecules, is proposed as the most stable complex. (c)2001 Elsevier Science.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11730333     DOI: 10.1006/abio.2001.5380

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  27 in total

1.  Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display.

Authors:  Christian Votsmeier; Hanna Plittersdorf; Oliver Hesse; Andreas Scheidig; Michael Strerath; Uwe Gritzan; Klaus Pellengahr; Peter Scholz; Andrea Eicker; David Myszka; Wayne M Coco; Ulrich Haupts
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 2.  Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors.

Authors:  Devesh Mewar; Anthony G Wilson
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 3.  Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.

Authors:  Raja K Sivamani; Heidi Goodarzi; Miki Shirakawa Garcia; Siba P Raychaudhuri; Lisa N Wehrli; Yoko Ono; Emanual Maverakis
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

4.  Recognition of human tumor necrosis factor α (TNF-α) by therapeutic antibody fragment: energetics and structural features.

Authors:  Jaka Marušič; Črtomir Podlipnik; Simona Jevševar; Drago Kuzman; Gorazd Vesnaver; Jurij Lah
Journal:  J Biol Chem       Date:  2012-01-19       Impact factor: 5.157

5.  Higher order structures of Adalimumab, Infliximab and their complexes with TNFα revealed by electron microscopy.

Authors:  Bich Ngoc Tran; Siew Leong Chan; Chloe Ng; Jian Shi; Ivan Correia; Czeslaw Radziejewski; Paul Matsudaira
Journal:  Protein Sci       Date:  2017-11-14       Impact factor: 6.725

6.  Adalimumab for the treatment of Crohn's disease.

Authors:  Andrea Cassinotti; Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Biologics       Date:  2008-12

Review 7.  [Systemic psoriasis therapy - the next step. Adalimumab].

Authors:  G Wozel; M Sticherling
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

8.  RPLC of intact proteins using sub-0.5 μm particles and commercial instrumentation.

Authors:  Benjamin J Rogers; Robert E Birdsall; Zhen Wu; Mary J Wirth
Journal:  Anal Chem       Date:  2013-07-02       Impact factor: 6.986

9.  Characterization of a novel anti-human TNF-alpha murine monoclonal antibody with high binding affinity and neutralizing activity.

Authors:  Moo Young Song; Sang Koo Park; Chang Seok Kim; Tae Hyoung Yoo; Bongtae Kim; Min Soo Kim; Yong Sung Kim; Won Jae Kwag; Byung Kyu Lee; Kwanghee Baek
Journal:  Exp Mol Med       Date:  2008-02-29       Impact factor: 8.718

10.  Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature.

Authors:  Jochen Schmitt; Gottfried Wozel
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.